Search results
Added:
6 months ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in…
View more
Added:
1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single…
View more
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Prof Marianna Fontana and Prof Arnt Kristen explore the management of transthyretin amyloid cardiomyopathy (ATTRCM) and discuss strategies for optimising patient care pathways.
View more
Added:
1 year ago
HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.00:24 - STEP HFpEF Programme: Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF & Semaglutide therapy and diuretic use in obesity-related HFpEF02:20 - EMPACT-MI: The effect of…
View more
Added:
1 year ago
Keep up to date with the top trials from AHA 24!CLEAR-SYNERGYSELECT-CABGSUMMITYELLOW IIIInternational Aortic Stenosis RegistryAMPLATZER IDEVALOR HCMWatch our full AHA 24 coverage in our Late-Breaking and Featured Science Collection.
View more
Added:
1 year ago
ACC 2025 - In this succinct video, Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute & University of California, CA, US) outlines the key late-breaking trials from the conference that are expected to have an impact on clinical practice.Trials covered in detail include:FRESH-UPAPI-CATALIGN-ARPROTECT-TAVIRecorded on-site at ACC in Chicago, 2025.Support: This is an independent interview…
View more
Added:
10 months ago
In this short interview, Dr Marat Fudim offers a preview of his upcoming manuscript, set to appear in the Sleep Disordered Breathing in Heart Failure special focus collection in Cardiac Failure Review. He discusses the evolving role of home sleep testing in diagnosing sleep apnea in patients with heart failure, addressing key considerations in clinical workflows and patient selection.Watch now to…
View more
Added:
1 year ago
Explore the cardiovascular breakthroughs shaping AHA 2024!Join renowned experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they preview the most impactful late-breaking studies poised to make waves at this year’s AHA Conference. Dive into their expert analysis and gain key insights into the studies that are set to drive the future of cardiovascular…
View more
Added:
1 year ago
HFA 2024 — Investigator, Prof Nicolas Girerd (University Hospital of Nancy, FR) joins us to discuss the findings from the TELESAT study (NCT06312501).This multicenter observational longitudinal cohort study investigated whether a Remote Patient Monitoring (RPM) program (Satelia®Cardio, Satelia) is able to prevent cardiac decompensation by detecting weak signals of decompensation early in patients…
View more
Added:
8 months ago
Learn about the management of HFrEF and HFpEF from Dr Michelle Kittleson (Cedars-Sinai Heart Institute, Los Angeles, US).This two-part video lecture series, part of Women As One's CLIMB® 2025 Skills Training Program, provides a comprehensive overview of key treatments and therapy approaches to cardiomyopathies.In this lecture, Dr Kittleson provides an in-depth review of the management of HFrEF…
View more